COVID-19
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
For the past year, Abbott Laboratories and Quest Diagnostics saw their revenue driven by COVID-19 diagnostics, but that seems to be changing as more and more vaccinated individuals are seeking medical advice for non-viral related issues.
As COVID-19 begins yet another surge across the U.S., there is some promising news about the effectiveness of vaccines. Here’s a look at some top COVID-19 stories.
WHO Investigators have attempted to return to the Wuhan lab to find the origins of the novel coronavirus but are now being blocked by the Chinese government.
The antibody is still being evaluated in clinical studies, with a large-scale Phase III trial expected to wrap in the second half of 2022.
A new study has found that statins, a popular class of cholesterol-lowering drugs, may decrease the odds of dying from coronavirus disease 2019 (COVID-19) by 41% and reduce the risk of severe disease.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
American health authorities have a dilemma. On one hand, COVID-19 booster shots for immunocompromised patients dramatically increase their immune response. On the other, in many parts of the world only a tiny fraction of the population have received even one dose of any COVID-19 vaccine. So, who should get the vaccines?
Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES